Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPR NASDAQ:GNLX NASDAQ:KROS NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$2.45-4.7%$2.37$0.69▼$3.94$518.17M0.968.44 million shs6.59 million shsGNLXGenelux$5.67+19.4%$3.82$1.99▼$5.89$179.42M-0.22136,522 shs368,482 shsKROSKeros Therapeutics$16.12+1.0%$15.20$9.12▼$72.37$648.22M0.97388,143 shs508,948 shsSIGASiga Technologies$8.44+1.9%$8.61$4.95▼$9.62$592.90M0.96484,910 shs240,123 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics-4.67%-15.52%-3.54%+105.88%+26.94%GNLXGenelux+19.37%+29.16%+54.50%+65.31%+116.41%KROSKeros Therapeutics+1.00%+3.47%+2.61%+11.63%-72.19%SIGASiga Technologies+1.93%-5.70%-3.65%+24.67%+29.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$2.45-4.7%$2.37$0.69▼$3.94$518.17M0.968.44 million shs6.59 million shsGNLXGenelux$5.67+19.4%$3.82$1.99▼$5.89$179.42M-0.22136,522 shs368,482 shsKROSKeros Therapeutics$16.12+1.0%$15.20$9.12▼$72.37$648.22M0.97388,143 shs508,948 shsSIGASiga Technologies$8.44+1.9%$8.61$4.95▼$9.62$592.90M0.96484,910 shs240,123 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics-4.67%-15.52%-3.54%+105.88%+26.94%GNLXGenelux+19.37%+29.16%+54.50%+65.31%+116.41%KROSKeros Therapeutics+1.00%+3.47%+2.61%+11.63%-72.19%SIGASiga Technologies+1.93%-5.70%-3.65%+24.67%+29.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.50Moderate Buy$7.00185.71% UpsideGNLXGenelux 2.50Moderate Buy$20.33258.61% UpsideKROSKeros Therapeutics 2.40Hold$30.0086.10% UpsideSIGASiga Technologies 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest GNLX, ESPR, KROS, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025SIGASiga TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025SIGASiga TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.007/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$332.31M1.49$0.02 per share106.97($1.97) per share-1.24GNLXGenelux$10K21,415.59N/AN/A$0.76 per share7.46KROSKeros Therapeutics$3.55M184.45N/AN/A$14.11 per share1.14SIGASiga Technologies$138.72M4.36$0.85 per share9.89$3.02 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$51.74M-$0.49N/AN/A43.30-35.84%N/A-28.41%11/6/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)KROSKeros Therapeutics-$187.35M$0.3152.00N/A2.068.06%2.96%2.74%11/5/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.476.75N/A45.73%40.52%35.62%11/6/2025 (Estimated)Latest GNLX, ESPR, KROS, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A11/5/2025Q3 2025KROSKeros Therapeutics-$1.11N/AN/AN/A$4.22 millionN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.150.76GNLXGeneluxN/A4.184.18KROSKeros TherapeuticsN/A21.1121.11SIGASiga TechnologiesN/A10.098.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%GNLXGenelux37.33%KROSKeros Therapeutics71.56%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.70%GNLXGenelux8.80%KROSKeros Therapeutics20.60%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableSIGASiga Technologies4071.61 million70.21 millionOptionableGNLX, ESPR, KROS, and SIGA HeadlinesRecent News About These CompaniesWeiss Ratings Reaffirms Hold (C) Rating for Siga Technologies (NASDAQ:SIGA)October 9 at 3:51 AM | marketbeat.comWealth Enhancement Advisory Services LLC Invests $394,000 in Siga Technologies Inc. $SIGAOctober 7 at 3:10 AM | marketbeat.comSiga Technologies (NASDAQ:SIGA) Stock Price Down 3.8% - Here's WhyOctober 6, 2025 | marketbeat.comInvestors Purchase Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)October 2, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Holdings in Siga Technologies Inc. $SIGASeptember 20, 2025 | marketbeat.comHarbor Capital Advisors Inc. Reduces Holdings in Siga Technologies Inc. $SIGASeptember 19, 2025 | marketbeat.comInvestors Buy Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)September 18, 2025 | marketbeat.comHealthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse...September 11, 2025 | marketbeat.comSIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA NewsAugust 20, 2025 | seekingalpha.comSIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)August 8, 2025 | finance.yahoo.comSIGA (SIGA) Q2 Revenue Soars 272%August 7, 2025 | theglobeandmail.comSIGA Technologies (SIGA) Reports Significant Earnings DeclineAugust 6, 2025 | finance.yahoo.comSIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA fundingAugust 6, 2025 | msn.comSIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Six Months Ended June 30, 2025August 5, 2025 | globenewswire.comSIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 ResultsJuly 29, 2025 | globenewswire.comSiga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to KnowJuly 24, 2025 | zacks.comSiga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should KnowJuly 15, 2025 | msn.comUS Market's Undiscovered Gems Featuring Three Promising Small CapsJuly 15, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Laps the Stock Market: Here's WhyJuly 9, 2025 | zacks.comSIGA Technologies Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, ESPR, KROS, and SIGA Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$2.45 -0.12 (-4.67%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$2.48 +0.02 (+1.02%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Genelux NASDAQ:GNLX$5.67 +0.92 (+19.37%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$5.50 -0.17 (-2.91%) As of 10/9/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Keros Therapeutics NASDAQ:KROS$16.12 +0.16 (+1.00%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$16.11 -0.01 (-0.06%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Siga Technologies NASDAQ:SIGA$8.44 +0.16 (+1.93%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$8.46 +0.03 (+0.30%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
